Short Interest in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Drops By 19.7%

KalVista Pharmaceuticals, Inc. (NASDAQ:KALVGet Rating) was the target of a large decline in short interest in April. As of April 15th, there was short interest totalling 874,800 shares, a decline of 19.7% from the March 31st total of 1,090,000 shares. Based on an average daily trading volume, of 209,900 shares, the short-interest ratio is presently 4.2 days. Currently, 4.2% of the company’s stock are sold short.

In related news, CEO Thomas Andrew Crockett sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 9th. The stock was sold at an average price of $17.07, for a total transaction of $170,700.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 6.40% of the company’s stock.

Large investors have recently bought and sold shares of the business. Monashee Investment Management LLC bought a new position in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $2,181,000. Two Sigma Advisers LP grew its stake in KalVista Pharmaceuticals by 550.2% in the 3rd quarter. Two Sigma Advisers LP now owns 120,422 shares of the specialty pharmaceutical company’s stock valued at $2,101,000 after purchasing an additional 101,900 shares during the period. Suvretta Capital Management LLC increased its position in shares of KalVista Pharmaceuticals by 29.6% during the 3rd quarter. Suvretta Capital Management LLC now owns 1,543,284 shares of the specialty pharmaceutical company’s stock valued at $26,930,000 after purchasing an additional 352,183 shares during the last quarter. Barclays PLC increased its position in shares of KalVista Pharmaceuticals by 105.2% during the 3rd quarter. Barclays PLC now owns 10,404 shares of the specialty pharmaceutical company’s stock valued at $181,000 after purchasing an additional 5,335 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth $334,000.

NASDAQ KALV traded down $0.50 on Tuesday, reaching $12.96. The company had a trading volume of 3,709 shares, compared to its average volume of 212,983. The business has a fifty day moving average price of $14.95. KalVista Pharmaceuticals has a 52-week low of $10.79 and a 52-week high of $30.70.

KalVista Pharmaceuticals (NASDAQ:KALVGet Rating) last announced its earnings results on Thursday, March 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by ($0.01). As a group, research analysts anticipate that KalVista Pharmaceuticals will post -3.45 EPS for the current fiscal year.

Several analysts recently issued reports on the stock. Needham & Company LLC reduced their price target on shares of KalVista Pharmaceuticals from $48.00 to $42.00 and set a “buy” rating for the company in a research report on Friday, March 11th. Roth Capital reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, March 8th. Zacks Investment Research upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $48.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, March 11th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $47.00.

KalVista Pharmaceuticals Company Profile (Get Rating)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Recommended Stories

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.